Lifecore signs CDMO manufacturing services agreement with aesthetics customer

Lifecore (LFCR) announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifecore will perform technical transfer services including process performance qualification batches for a sterile product that the customer currently manufactures in-house, outside the U.S. Initial outsourced manufacturing aims to increase production for products sold in the U.S. market. Lifecore believes the product may generate commercial revenue within 24 months, contributing to the company’s targeted 2029 revenue CAGR of 12%. This is the third commercial site transfer Lifecore has signed since October 2025, demonstrating the successful execution of the company’s strategic plan to secure lower risk, late-stage programs and site transfers which typically provide a faster and more predictable path to commercial revenue compared to traditional development programs. It is also an example of the company’s service expansion into new therapeutic modalities.